Thus, although KIF20A, KIF14, KIF4A, KIFC1 and KIF2C have been proposed as novel targets for cancer therapy, our data suggest that they might not be very effective in p53-mutant lung cancer cells. This evidence concerns the gene TP53 and lung carcinoma.